



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 31/445</b>		A1	(11) International Publication Number: <b>WO 98/39000</b> (43) International Publication Date: 11 September 1998 (11.09.98)
(21) International Application Number: PCT/IB98/00508			(81) Designated States: AU, CA, CN, IL, JP, KR, MX, NO, NZ, SG, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 3 March 1998 (03.03.98)			
(30) Priority Data: 60/039,832 3 March 1997 (03.03.97) US			<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: EISAI CO., LTD. [JP/JP]; 4-6-10, Koishikawa, Bunkyo-ku, Tokyo 112-88 (JP).			
(71)(72) Applicant and Inventor: ROGERS, Sharon, L. [US/US]; 3-9-15, Mejiro, Toshima-ku, Tokyo 171 (JP).			
(72) Inventors: FRIEDHOFF, Lawrence, T.; 525 Riverdale Road, Riverdale, NJ 07675 (US). TISEO, Paul, J.; 166 East 63rd Street, New York, NY 10021 (US).			
(74) Agents: WILDMAN, David, E. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US).			

(54) Title: USE OF CHOLINESTERASE INHIBITORS TO TREAT DISORDERS OF ATTENTION

## (57) Abstract

The present invention provides novel methods of treating disorders of attention or improving attention in humans by administering an effective amount of a cholinesterase inhibitor.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10

15

USE OF CHOLINESTERASE INHIBITORS  
TO TREAT DISORDERS OF ATTENTION

Field of the Invention

This invention relates to the use of cholinesterase inhibitor compounds for treatment of disorders of attention, such as Attention Deficit Disorder (ADD). The compounds are also useful as a replacement for other substances which patients commonly use to self-medicate for these disorders, and which can have undesirable side effects.

25 Background of the Invention

Disorders of attention are a significant public health problem. Primary attention deficit disorder is estimated to affect 6 to 9 percent of school aged children (Anderson, J.C. et al. *Arch. Gen. Psych.* 44:69 (1987); Safer, D.J. et al. *JAMA* 260:2256 (1988)). Well-designed follow-up studies have demonstrated that 30 this disorder is not confined to childhood but is present in up to 50 percent of young adults who have the disorder as children (Mannuzza, S. et al. *Arch. Gen. Psych.*

50:565; Willens, T.E. et al. In Nadeau, K. Ed. *A Comprehensive Guide to Attention Deficit Disorder*, Brunne/Mazel, Inc. New York, (1993). This suggests that up to 2 to 4 percent of the adults in the United States may exhibit symptoms of a primary attention deficit disorder. Disorders of attention often lead to poor performance in  
5 school and at work and are correlated with antisocial behavior. These behaviors carry a high cost to individuals in lost time and effort, as well as imposing direct costs on society.

Attention disorders are also associated with indirect costs. For example, there is evidence that patients with attention disorders often "self-medicate" in destructive ways. These patients have a higher than average incidence of cigarette smoking and alcoholism. They also have a higher than average incidence of illegal drug use (Barkley, R.A. In *Attention Deficit Hyperactivity Disorder*, Guilford Press, New York, (1990) Chapter 4, pp. 106-129). Thus, an effective treatment for attention disorders would be also be a useful treatment for  
10 some substance dependencies.  
15

Current approved treatments for attention deficit disorder are limited to drugs that affect amine metabolism in the brain (Spencer, T. et al. *J. Am. Acad. Child Adolesc. Psych.* 35:409 (1996)). These drugs have significant limitations including side effects and abuse potential, making currently available treatments  
20 controversial. Such medications include the stimulants methylphenidate and dextroamphetamine. Pemoline is another stimulant sometimes used to treat attention deficit disorder in children. These stimulant drugs can have cardiac side effects, which are less pronounced in the case of methylphenidate. These stimulants can also cause growth suppression in children, and are potentially  
25 addictive for adolescents and adults.

Current alternatives to stimulants for the treatment of attention disorders are the tricyclic antidepressents and clonidine. The use of tricyclic antidepressants is more likely than the use of stimulants to cause cardiac arrhythmias in children. However, because of the likelihood of stimulant abuse by

adolescents and adults with attention disorders, tricyclic antidepressants and clonidine are often tried first (Maxmen, J.S. and Ward, N.G. *Essential Psychopathology and Its Treatment*, p. 443, Second Edition, Norton & Co., New York, (1995))

5           Recent studies have shown that nicotine may be an effective treatment for attention deficit disorder (Levin, E.D. et al. *Psychopharmacology* 123:55 (1996)). However, nicotine acts at multiple pharmacological sites in the body, can be addictive and also has undesirable side effects, and its mode of action is not known. It is not known, for example, which of nicotine's pharmacological  
10          effects are responsible for the increased attention displayed by subjects to whom nicotine was administered.

Impaired attention may also be a characteristic of Alzheimer's disease, although Alzheimer's patients typically remain alert (Coyle et al., Alzheimer's Disease: A Disorder of Cholinergic Innervation, *Science* 219:1184-90  
15          (1983)), and the underlying disorders and known treatments are very different (Grady, C.L. et al. *J. Clin. Exp. Neuropsychology* 10:576 (1988)). Alzheimer's disease involves progressive and profound loss of memory, postulated to involve a deficiency in brain cortical acetylcholine affecting cholinergic synapses. This deficiency is thought to be caused by selective degeneration of acetylcholine-releasing neurons (Coyle, *supra*). Disorders of attention and ADD, which are concerned with mental concentration as opposed to memory, are not thought to be caused by acetylcholine deficiencies.  
20

Certain synapses of the brain use acetylcholine as a neural transmitter, to transmit messages across the synapse to a cholinergic receptor. During normal transmission, acetylcholine crosses the synaptic gap to carry the message by stimulating the cholinergic receptor. Memory is thought to be related, at least in part, to post-synaptic changes which occur as a result of the timing and strength of acetylcholine stimulation during learning, with certain experiences tending to block or facilitate corresponding neural pathways, *i.e.* making it more or less difficult to  
25

stimulate the same post-synaptic receptor at a future time (Deutsch, The Cholinergic Synapse and the Site of Memory, *Science* 174:788-94 (1971)). Acetylcholine also is rapidly destroyed by the enzyme cholinesterase. Thus, insufficient acetylcholine or excess cholinesterase can interfere with synaptic transmission by too rapidly destroying the acetylcholine message, resulting in weak cholinergic stimulation which can be experienced as memory loss. When this condition is chronic, *i.e.* from degeneration of acetylcholine-releasing neurons, the Alzheimer's syndrome may develop. One way of counteracting this imbalance is by interfering with the ability of cholinesterase to degrade acetylcholine, as by treatment with a cholinesterase inhibitor (Sugimoto et al., U.S. Patent No. 4,895,841).

Attention is related to memory in that attention is a prerequisite to memory. Disorders of attention or learning, including ADD, do not typically involve memory loss, and are characterized by symptoms such as motor restlessness, short attention span, poor concentration and organizational skills, impulsive behavior, and lack of task persistence. The cause or causes of ADD is unknown. Several theories have been proposed, and include impaired ability of the frontal lobes to process current experiences and integrate them with memory (frontal lobe disinhibition), as well as abnormalities or imbalances in one or more of dopamine and norepinephrine in the brain (the catecholeamine hypothesis). However, studies of these catecholamines in both animals and man, as well as other neurotransmitters such as serotonin, have yielded inconsistent results regarding the biochemical basis for ADD. Although impaired use of dopamine, norepinephrine, and serotonin is implicated in ADD, the underlying neurochemical dysfunction is not well understood, nor are there satisfactory and well-recognized therapies for ADD.

Thus, a need exists for additional therapies which effectively treat disorders of attention generally, and ADD specifically. Therapies which are specific to loss of attention, and which are not addictive, do not promote cardiac

imbalance, and do not have other undesirable characteristics are particularly needed.


### Summary of the Invention

5 It has now been surprisingly discovered that augmentation of cholinergic transmission is an effective treatment for attention deficit disorder. It has also been discovered that the compounds of this invention are useful for the treatment of disorders of attention, including attention deficit disorder.

Cholinesterase inhibitors provide one method of augmenting cholinergic 10 transmission. They tend to be associated with fewer side effects than other methods because they augment the effects of endogenous acetylcholine rather than acting directly. Additionally, cholinesterase inhibitors are more specific to areas of the body where endogenous acetylcholine is being released. They have a longer duration of action than nicotine, which is rapidly metabolized. Donepezil hydrochloride and its congeners are 15 cholinesterase inhibitors that offer the additional advantage of specificity for acetylcholinesterase, the predominant form of the enzyme in the brain. For example, donepezil hydrochloride has approximately 1200-fold specificity for acetylcholinesterase relative to butyrylcholinesterase, the most common cholinesterase outside the brain and central nervous system.

20 The present invention provides novel methods of treating disorders of attention in humans by administering an effective amount of a cholinesterase inhibitor. More particularly, the invention provides a method for treating disorders of attention by administering to a human in need of such treatment an effective amount of a compound of the formula:

25



in which J is

- (a) a group, substituted or unsubstituted, selected from the group consisting of (1) phenyl, (2) pyridyl, (3) pyrazyl, (4) quinolyl, (5) cyclohexyl, (6) 30 quinoxalyl and (7) furyl;

(b) a monovalent or divalent group, in which the phenyl may have a substituent(s), selected from the group consisting of (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl and (9)  $C_6H_5-CO-CH(CH_3)-$ ;


- 5                   (c) a monovalent group derived from a cyclic amide compound;  
                  (d) a lower alkyl or  
                  (e) a group of  $R^{21}-CH=CH-$  in which  $R^{21}$  is hydrogen or a lower alkoxy carbonyl;

B is  $-(CHR^{22})_r-, -CO-(CHR^{22})_r-, -NR^4-(CHR^{22})_r-, R^4$  being

- 10                  hydrogen, a lower alkyl, an acyl, a lower alkylsulfonyl, phenyl, a substituted phenyl, benzyl or a substituted benzyl,  $-CO-NR^5-(CHR^{22})_r-, R^5$  being hydrogen, a lower alkyl or phenyl,  $-CH=CH-(CHR^{22})_r-, -OCOO-(CHR^{22})_r-,$   
 $-OOC-NH-(CHR^{22})_r-, -NH-CO-(CHR^{22})_r-, -CH_2-CO-NH-(CHR^{22})_r-,$   
 $-(CH_2)_2-NH-(CHR^{22})_r-, -CH(OH)-(CHR^{22})_r-, r$  being zero or an integer of 1 to  
15                  10,  $R^{22}$  being hydrogen or methyl so that one alkylene group may have no methyl branch or one or more methyl branch,  $=(CH-CH=CH)_b-, b$  being an integer of 1 to 3,  
 $=CH-(CH_2)_c-, c$  being zero or an integer of 1 to 9,  $=(CH-CH)_d-, d$  being zero or an integer of 1 to 5;  $-CO-CH=CH-CH_2-, -CO-CH_2-CH(OH)-CH_2-,$   
 $-CH(CH_3)-CO-NH-CH_2-, -CH=CH-CO-NH-(CH_2)_2-, -NH-, -O-,$   
20                   $-S-,$  a dialkylaminoalkylcarbonyl or a lower alkoxy carbonyl;

T is a nitrogen or carbon;

Q is nitrogen, carbon or



and q is an integer of 1 to 3;

- 25                  K is hydrogen, phenyl, a substituted phenyl, an arylalkyl in which the phenyl may have a substituent, cinnamyl, a lower alkyl, pyridylmethyl, a cycloalkylalkyl, adamantane methyl, furylmethyl, a cycloalkyl, a lower alkoxy carbonyl or an acyl; and  
                    $---$  shows a single bond or a double bond.

In the compounds having the formula (XXV), it is preferable that J is (a)

- 30                  or (b). In the definition (b), monovalent groups of (2), (3) and (5) and divalent groups of

(2) are preferable. In the definition of  $B, -(CHR^{22})_r-, =(CH-CH=CH)_b-, =CH-(CH_2)_c-$  and  $=(CH-CH)_d=$  are preferable. These preferable groups of (B) may be connected with (b) of J, in particular (2) of (b).

It is preferable in the formula (XXV) that Q is nitrogen, T is carbon and q 5 is 1 or 3; and Q is carbon, T is nitrogen and q is 2. It is most preferable that Q is nitrogen, T is carbon and q is 2.

It is preferable that K is a phenylalkyl or a phenylalkyl having a substituent(s) on the phenyl.

Preferable compounds have the above shown formula in which J is (b).

10 The group (b) includes ten groups having the respective formulae shown below. S is hydrogen or a substituent such as a lower alkyl having 1 to 6 carbon atoms and a lower alkoxy having 1 to 6 carbon atoms and t is an integer of 1 to 4. Among the substituents, methoxy is most preferred. The phenyl is most preferred to have 1 to 3 methoxy groups. (S)<sub>t</sub> may form a methylene dioxy group or ethylene dioxy group on two adjacent 15 carbon atoms of the phenyl group.

A preferable definition of B includes  $-(CHR^{22})_r-, -CO-(CHR^{22})_r-, =(CH-CH=CH)_b-, =CH-(CH_2)_c-$  and  $=(CH-CH)_d=$ . The group  $-(CHR^{22})_r-$  in which R<sup>22</sup> is hydrogen and r is an integer of 1 to 3 and then the group  $=CH-(CH_2)_c-$  are most preferable.


20 In the above defined cyclic amine compounds of the methods of the invention, it is preferable that J in the formula is (b), the monovalent or divalent group. In the definition (b), indanonyl, indanedionyl and indenyl are most preferable, optionally having one or more substituents on the phenyl.

In the definition  $B, -(CHR^{22})_r-$  and  $=CH-(CH_2)_c-$  are preferable.

25 The ring including T and Q may be a 5-, 6-or 7-membered ring. It is preferable that Q is nitrogen, T is carbon or nitrogen and n is 2; Q is nitrogen, T is carbon and n is 1 or 3; and Q is carbon, T is nitrogen and n is 2.

In the definition K, phenyl, an arylalkyl and cinnamyl are preferable, optionally having one or more substituents on the phenyl.

## (b) Substituents




More preferably, the method comprises treating disorders of attention by  
 20 administering an effective amount of a compound selected from the group consisting of:  
 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,  
 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-ylidanyl)methylpiperidine,  
 1-benzyl-4-((5-methoxy-1-indanon)-2-yl)methylpiperidine,  
 1-benzyl-4-((5,6-diethoxy-1-indanon)-2-yl)methylpiperidine,  
 25 1-benzyl-4-((5,6-methylenedioxy-1-indanon)-2-yl)methylpiperidine,  
 1-(m-nitrobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,  
 1-cyclohexymethyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,  
 1-(m-florobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,  
 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)propylpiperidine,  
 30 1-benzyl-4-((5-isopropoxy-6-methoxy-1-indanon)-2-yl)methylpiperidine  
 and

1-benzyl-4-((5,6-dimethoxy-1-oxoindanon)-2-yl)propenylpiperidine.

Most preferably, the method comprises treating disorders of attention by administering an effective amount of the compound

1-benzyl-4-((5,6-dimethoxy-1-indanon)- 2-yl)methylpiperidine.

5




10

#### Detailed Description of the Invention

The invention is explained in detail in view of the piperidine compounds which fall within the scope of the above defined cyclic amine compound. It will be understood, however, that this explanation applies to the use of the entire group of cyclic 15 amine compounds for the treatment of attention disorders.


The piperidine compounds of the methods of the invention are defined by the formula (I):



20

wherein R<sup>1</sup> is the following substituted or unsubstituted group: 1) a phenyl group, 2) a pyridyl group, 3) a pyrazyl group, 4) a quinolyl group, 5) an indanyl group, 6) a cyclohexyl group, 7) a quinoxalyl group, or 8) a furyl group; a monovalent or divalent 25 group derived from an indanone having an unsubstituted or substituted phenyl ring; a monovalent group derived from a cyclic amide compound; a lower alkyl group or a group represented by the formula R<sup>3</sup> —CH=C— (wherein R<sup>3</sup> is a hydrogen atom or a lower alkoxy carbonyl group),

X is a member selected from the group represented by the formulas



a dialkylaminoalkylcarbonyl group, and a lower alkoxy carbonyl group, wherein R<sup>4</sup> is a hydrogen atom, a lower alkyl group, an acyl group, a lower alkylsulfonyl group, or a substituted or unsubstituted phenyl or benzyl and R<sup>5</sup> is a hydrogen atom, a lower alkyl group, or a phenyl group, and wherein the n's in the above definition of X are each independently an integer of 0 to 6,

R<sup>2</sup> is a substituted or unsubstituted phenyl group, a substituted or unsubstituted arylalkyl group, a cinnamyl group, a lower alkyl group, a pyridylmethyl group, a cycloalkylalkyl group, an adamantanemethyl group, or a furoylmethyl group, and the symbol, — means a single bond or a double bond.


The term "lower alkyl group" used in the above definition of R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> with respect to the compound (I) of the present invention is intended to mean a straight-chain or branched alkyl group having 1 to 6 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl (amyl), isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl,

1,2-dimethylpropyl, hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl,  
 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl,  
 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl,  
 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, and  
 5 1-ethyl-2-methylpropyl groups. Among these, methyl, ethyl, propyl, and isopropyl  
 groups are preferable. A methyl group is the most preferable.

Examples of the substituents (1)-(8) in the definition of R<sup>1</sup> above include lower alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl groups; lower alkoxy groups corresponding 10 to the above-described lower alkyl groups, such as methoxy and ethoxy groups; a nitro group; halogen atoms such as chlorine, bromine, and fluorine; a carboxyl group; lower alkoxy carbonyl groups corresponding to the above-described lower alkoxy groups, such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, n-propoxycarbonyl, and n-butyloxycarbonyl groups; an amino group; a lower monoalkylamino group; a lower 15 dialkylamino group, a carbamoyl group; acylamino groups derived from aliphatic saturated monocarboxylic acids having 1 to 6 carbon atoms, such as acetylamino, propionylamino, butyrylamino, isobutyrylamino, valeryl amino, and pivaloylamino groups; cycloalkyloxycarbonyl groups such as a cyclohexyloxycarbonyl group; lower alkylaminocarbonyl groups such as methylaminocarbonyl and ethylaminocarbonyl 20 groups; lower alkylcarbonyloxy groups corresponding to the above-defined lower alkyl groups, such as methylcarbonyloxy, ethylcarbonyloxy, and n-propylcarbonyloxy groups; halogenated lower alkyl groups including a trifluoromethyl group; a hydroxyl group; a formyl group; and lower alkoxy lower alkyl groups such as ethoxymethyl, methoxymethyl, and methoxyethyl groups. The "lower alkyl groups" and "lower alkoxy 25 groups" in the above description of the substituent include all the groups derived from the above-mentioned groups. The substituent may be one to three of them which may be the same or different.


When the substituent is a phenyl group, the following group is within the scope of the substituted phenyl group:

30



wherein G is a member of a group selected from the formulas —O—, —CH<sub>2</sub>—O—; —CH<sub>2</sub>—SO<sub>2</sub>—,

5



10 and a group represented by the formula

15

Preferable examples of the substituents for the phenyl group include lower alkyl, lower alkoxy, nitro, halogenated lower alkyl, lower alkoxy carbonyl, formyl, hydroxyl, and lower alkoxy lower alkyl groups, halogen atoms, and benzoyl and benzylsulfonyl groups. The substituent may be two or more of them which may be the same or different.

Preferable examples of the substituent for the pyridyl group include lower alkyl and amino groups and halogen atoms.

Preferable examples of the substituent for the pyrazyl group include lower alkoxy carbonyl, carboxyl, acylamino, carbamoyl, and cycloalkyloxycarbonyl groups.


25

With respect to R<sup>1</sup>, the pyridyl group is preferably a 2-pyridyl, 3-pyridyl, or 4-pyridyl group; the pyrazyl group is preferably a 2-pyrazinyl group; the quinolyl group is preferably a 2-quinolyl or 3-quinolyl group; the quinoxaliny group is preferable a 2-quinoxaliny or 3-quinoxaliny group; and the furyl group is preferably a 2-furyl group.

30

Specific examples of preferable monovalent or divalent group derived from an indanone having an unsubstituted or substituted phenyl ring include those represented by the following formulae (II) and (III):

5



10

wherein each m is an integer from 1 to 4 and each A, which may be the same or different, is one of the substituents described in the above items (1) to (8) of the definition of R<sup>1</sup> or a hydrogen atom, preferably a hydrogen atom (i.e. unsubstituted), a lower alkyl group, or a lower alkoxy group, and most preferably the indanone group is  
15 unsubstituted or substituted with 1 to 3 methoxy groups.


20

Examples of the monovalent group derived from a cyclic amide compound include quinazolone, tetrahydroisoquinolinone, tetrahydrobenzodiazepinone, and hexahydrobenzazocinone. However, the monovalent group may be any one having a cyclic amide group in the structural formula thereof and is not limited to the


25

above-described specific examples only. The cyclic amide group may be one derived from a monocyclic or condensed heterocyclic ring. The condensed heterocyclic ring is preferably one formed by condensation with a phenyl ring. In this case, the phenyl ring may be substituted with a lower alkyl group having 1 to 6 carbon atoms, preferably a methyl group, or a lower alkoxy group having 1 to 6 carbon atoms, preferably a methoxy group. Preferable examples of the monovalent group include the following groups:


5




10




15





20



25



30



(a)

(h)

(b)

(i)

(c)

(j)

(d)







(k)

(e)

(l)

(f)

(m)



In the above formulae, Y's in the formulae (i) and (l) are each a hydrogen atom or a lower alkyl group, V in the formula (k) is a hydrogen atom or a lower alkoxy group, W<sup>1</sup> and W<sup>2</sup> in the formulae (m) and (n) are each a hydrogen atom, a lower alkyl group, or a lower alkoxy group and W<sup>3</sup> is a hydrogen atom or a lower alkyl group.

5       The right-hand ring in each of the formulae (j) and (l) is a seven-membered ring, while the right-hand ring in the formula (k) is an eight-membered ring.

10      The most preferable examples of the above-defined R<sup>1</sup> include a monovalent group derived from an indanone having an unsubstituted or substituted phenyl group and a monovalent group derived from a cyclic amide compound.

15      The most preferable examples of the above-defined X include a group represented by the formula —(CH<sub>2</sub>)<sub>n</sub>—, a group having an amide group, and groups represented by the above formulae wherein n is 2. Therefore, it is most preferable that any portion of a group represented by the formula R<sup>1</sup>—X— have a carbonyl or amide group.

The substituents involved in the expressions "a substituted or unsubstituted phenyl group" and "a substituted or unsubstituted arylalkyl group" in the above definition of R<sup>2</sup> are the same as those described in the above items (1) to (8) of the definition for R<sup>1</sup>.

20      The term "arylalkyl group" is intended to mean an unsubstituted benzyl or phenethyl group, etc.

Specific examples of the pyridylmethyl group include 2-pyridylmethyl, 3-pyridylmethyl, and 4-pyridylmethyl groups.

25      Preferable examples of R<sup>2</sup> include benzyl and phenethyl groups. The symbol

— means either a single or a double bond. This bond is a double bond only when R<sup>1</sup> is the above-described divalent group (III) derived from an indanone having an unsubstituted or substituted phenyl ring, while it is a single bond in other cases.

30      Moreover, the compounds of the present invention may have an asymmetric carbon atom depending upon the kind of the substituent and, therefore, have stereoisomers. They are, of course, within the scope of the present invention.

When R<sup>1</sup> has an indanone skeleton, the compound of the present invention has an asymmetric carbon atom and, therefore, may have stereoisomers, optical isomers, diastereomers, etc. All of these isomers are within the scope of the present invention.

- In the present invention, the term "pharmacologically acceptable salt"
- 5 includes those of inorganic acids, such as hydrochloride, sulfate, hydrobromide, and phosphate, and those of organic acids, such as formate, acetate, trifluoroacetate, methanesulfonate, benzenesulfonate, and toluenesulfonate. Further, when a certain kind of substituent is selected, the compound of the present invention may form, e.g., alkali metal salts such as a sodium or potassium salt, alkaline earth metal salts such as a
- 10 calcium or magnesium salt, organic amine salts such as a salt with trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine, or N,N'-dibenzylethylenediamine.

- In practicing the methods of the invention, the acetylcholinesterase inhibitor compounds of the present invention may be orally or parenterally administered. In general, they are parenterally administered in the form of injections, such as
- 15 intravenous, subcutaneous, and intramuscular injections, suppositories, or sublingual tablets. The dose will vary depending upon the symptoms, age, sex, weight, and sensitivity of patients, method of administration, time and intervals of administration and properties, dispensing, and kind of pharmaceutical preparations, kind of effective ingredients, etc., so that there is no particular limitation with respect to the dose.
- 20 Normally the compound may be administered in a dose of about 0.1 to 300 mg, preferably 1 to 100 mg, per day per patient, ordinarily in one to four portions.

Pharmaceutical preparations in the dosage form of, e.g., injections, suppositories, sublingual tablets, tablets, and capsules are prepared according to methods which are commonly accepted in the art.

- 25 In preparing injections, the effective ingredient is blended, if necessary, with a pH modifier, a buffer, a suspending agent, a solubilizing agent, a stabilizer, a tonicity agent, a preservative, etc., followed by preparation of an intravenous, subcutaneous, or intramuscular injection according to an ordinary method. In this case, if necessary, it is possible to lyophilize these preparations according to an ordinary
- 30 method.

Examples of the suspending agents include methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, powdered tragacanth, sodium carboxymethylcellulose, and polyoxyethylene sorbitan monolaurate.

5 Examples of the solubilizing agent include polyoxyethylene hydrogenated castor oil, Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, Macrogol, and an ethyl ester of castor oil fatty acid.

Examples of the stabilizer include sodium sulfite, sodium metasulfite, and ether, and examples of the preservative include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol, and chlorocresol.


10 The compounds of the methods of the present invention may be prepared by various processes. A representative process for the synthesis of the compound 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]-methylpiperidine hydrochloride is detailed below as Example 1. Other representative processes for preparing the compounds used in the methods of the present invention can be found in U.S. Patent 4,895,841, 15 incorporated herein by reference in its entirety.

Example 1: Synthesis of Donepezil Hydrochloride

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine

20 A. Preparation of First Precursor

1-benzyl-4-piperidine-carboaldehyde having the formula:



25 was prepared in the following way.

26 grams of methoxymethylene-triphenylphosphonium chloride was suspended in 200 ml of anhydrous ether. A 1.6M solution in hexane of n-butyl lithium was added dropwise to the suspension at room temperature. The mixture was stirred at room temperature for 30 minutes and cooled down to 0°C. Then 30 ml of a solution in 30 anhydrous ether of 14.35 g of 1-benzyl-4-piperidone was added to the mixture. It was stirred at room temperature for 3 hours and filtrated to remove the insolubles. The

filtrate liquid was concentrated at a reduced pressure. The obtained concentrate was dissolved in ether and extracted with 1N hydrochloric acid. An aqueous solution of sodium hydroxide was added to the extract to give a pH value of 12, followed by extraction with methylene chloride. The extract was dried with magnesium sulfate and 5 concentrated at a reduced pressure. The residue was purified with a column filled with silica gel to obtain 5.50 g of an oil with a yield of 33 percent.


The oil was incorporated into 40 ml of methanol and 40 ml of 1N hydrochloric acid was added to the solution. It was heated so as to reflux for 3 hours and then concentrated at a reduced pressure. The residue was dissolved in water. An 10 aqueous solution of sodium hydroxide was added to the solution to give a pH value of 12 and the solution was extracted with methylene chloride. The extract was washed with saturated salt solution and dried with magnesium sulfate. It was further concentrated at a reduced pressure and the residue was purified in a column charged with silica gel. 2.77 g of the intended compound was obtained with a yield of 54 percent. In analysis, its 15 molecular formula was found to be C<sub>13</sub>H<sub>17</sub>NO and <sup>1</sup>H--NMR (CDCl<sub>3</sub>)δ, 1.40-2.40 (7H, m), 2.78 (2H, dt), 3.45 (2H, S), 7.20 (5H, S), 9.51 (1H, d).

This compound may also be produced according to the methods shown in (1) Arm. Kim. Zh., 36(9), 614-17 (1983) by R. A. Kuroyan, A. I. Markosyan, G. M. Snkhchyan and S. A. Vartangan and (2) Ind. Chim. Belge, 32, 64-5 (1967) by B. 20 Hermans and P. Van Daele.

#### B. Preparation of Second Precursor

1-Benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidenyl-methyl]piperidine hydrochloride:

25



was prepared via a reaction conducted in an argon atmosphere.


30 2.05 ml of diisopropylamine was added to 10 ml of anhydrous THF, followed by addition of 9.12 ml of a 1.6M solution of n-butyllithium in hexane at 0°C.

The mixture was stirred at 0°C. for 10 min and then cooled to -78°C., and a solution of 2.55 g of 5,6-dimethoxy-1-indanone in 30 ml of anhydrous THF and 2.31 ml of hexamethyl-phosphoric amide were added . The mixture was stirred at -78°C. for 15 min, and a solution of 2.70 g of 1-benzyl-4-piperidinecarboaldehyde in 30 ml of 5 anhydrous THF was added . The temperature of the mixture was gradually raised to room temperature, followed by stirring for 2 hr. An aqueous 1% ammonium chloride solution was added , and the organic phase was separated. The water phase was extracted with ethyl acetate, and the organic phases were combined with each other. The combined organic phase was washed with a saturated saline solution, dried over 10 magnesium sulfate, and concentrated in vacuo. The resulting residue was purified on a silica gel column (methylene chloride:methanol=500:1-100: 1). The eluate was concentrated in vacuo, and the residue was dissolved in methylene chloride. A 10% solution of hydrochloric acid in ethyl acetate was added to the resulting solution, followed by concentration in vacuo to obtain a crystal, which was recrystallized from 15 methanol/IPE to obtain 3.40 g (yield: 62%) of the title compound having the following properties: m.p. (°C.): 237°-238°C. (dec.) elementary analysis: C<sub>24</sub>H<sub>27</sub>NO<sub>3</sub>.HCl. C (69.64% calculated; 69.51% found). H (6.82% calculated; 6.78% found). N (3.38% calculated; 3.30% found).

20       C. Donepezil Hydrochloride

1-Benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]-methylpiperidine hydrochloride (donepezil hydrochloride):

25



was prepared from the precursors as follows.

0.4 g of

1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidenyl]methylpiperidine was dissolved in 16 30 ml of THF, followed by addition of 0.04 g of 10% palladium-carbon. The mixture was hydrogenated at room temperature under atmospheric pressure for 6 hr. The catalyst

was filtered off, and the filtrate was concentrated in vacuo. The residue was purified by making use of a silica gel column (methylene chloride: methanol=50: 1). The eluate was concentrated in vacuo, and the residue was dissolved in methylene chloride. A 10% solution of hydrochloric acid in ethyl acetate was added to the resulting solution,  
 5 followed by concentration in vacuo to obtain a crystal, which was recrystallized from methanol/IPE to obtain 0.36 g (yield: 82%) of the title compound having the following properties: m.p. (°C.): 211°-212°C. (dec.) elementary analysis: C<sub>24</sub>H<sub>29</sub>NO<sub>3</sub>.HCl. C (69.30% calculated; 69.33% found). H (7.27% calculated; 7.15% found). N (3.37% calculated; 3.22% found).

10

#### Example 2 - Utility for Attention Disorders

The effects of the cholinesterase inhibitor donepezil hydrochloride on the cognitive performance of patients with Alzheimer's disease was evaluated in a 15-week, multi-center, double-blind, placebo-controlled trial of 458 patients. This study

15 administered donepezil hydrochloride (5 or 10 mg) or placebo to patients in a blinded fashion for a period of 24 weeks, followed by 3 weeks of single-blind placebo.

Psychometric evaluations were conducted at 3 week intervals during the study. One hundred fifty patients received 5 mg doses, 156 received 10 mg doses, and 156 received a matching placebo. Effects on attention were evaluated using the Attention/Calculation  
 20 element of the Mini-Mental Status Examination (MMSE). Improvement in attention and calculation performance is indicated by positive values, deterioration is indicated by negative values. The analysis of this domain of the study is presented in Table 1.

TABLE 1							
MMSE-Attention and Calculation Domain Intent to Treat Population Study-301							
				Pair-wise Comparison/p-values			
Week	Placebo (A)	Donepezil HCl 5 mg/day (B)	Donepezil HCl 10 mg/day (C)	Overall	A vs. B	A vs. C	B+C vs. A
30	Baseline [Adjusted Mean (SE)]	3.351 (0.146)	3.468 (0.143)	3.247 (0.143)	0.5515		

TABLE 1

## **MMSE-Attention and Calculation Domain Intent to Treat Population Study-301**

				Pair-wise Comparison/p-values			
Week	Placebo (A)	Donepezil HCl 5 mg/day (B)	Donepezil HCl 10 mg/day (C)	Overall	A vs. B	A vs. C	B+C vs. A
Week 12	-0.123 (0.110)	0.153 (0.109)	0.248 (0.116)	0.0417*	0.0647	0.0164*	0.0137
Endpoint	-0.94 (0.106)	0.66 (0.106)	0.354 (0.107)	0.0422*	0.2728	0.0121*	0.037*

\* Statistically significant change from baseline  $0.001 < p < 0.05$

5 A 30-week, multi-center, double-blind, placebo-controlled trial of 458 patients was also conducted in patients with Alzheimer's disease. As in the first study, donepezil hydrochloride (5 or 10 mg) or placebo was administered to patients in a blinded fashion for a period of 24 weeks followed by 6 weeks of single-blind placebo.

10 Psychometric evaluations were conducted at 6 week intervals during the study. One hundred fifty four patients received 5 mg doses, 154 received 10 mg doses, and 150 received a matching placebo. Effects on attention were evaluated using the Attention/Calculation element of the Mini-Mental Status Examination (MMSE). Improved attention and calculation performance is indicated by positive values, deterioration is indicated by negative values. The analysis of this domain of the study is

15 presented in Table 2.

TABLE 2

## **MMSE-Attention and Calculation Domain Intent to Treat Population Study-302**

				Pair-wise Comparison/p-values			
Week	Placebo (A)	Donepezil HCl 5 mg/day (B)	Donepezil HCl 10 mg/day (C)	Overall	A vs. B	A vs. C	B+C vs. A
Baseline [Adjusted Mean (SE)]	3.351 (0.158)	3.468 (0.143)	3.085 (0.164)	0.734			

TABLE 2							
MMSE-Attention and Calculation Domain Intent to Treat Population Study-302				Pair-wise Comparison/p-values			
Week	Placebo (A)	Donepezil HCl 5 mg/day (B)	Donepezil HCl 10 mg/day (C)	Overall	A vs. B	A vs. C	B+C vs. A
Week 12	-0.55 (0.117)	0.153 (0.109)	0.361 (0.123)	0.0235*	0.0316*	0.0113*	0.0067
Week 24	-0.187 (0.126)	0.116 (0.128)	0.160 (0.143)	0.1086	0.0811	0.0624	0.0354
Endpoint	-0.216 (0.117)	0.66 (0.106)	0.070 (0.121)	0.1346	0.0855	0.0823*	0.0454

\* Statistically significant change from baseline  $0.001 < p < 0.05$

5


Beneficial effects of donepezil hydrochloride on attention were also observed in a study of healthy volunteers who received single 5 or 10 mg daily doses for a total of 3 weeks. One of these subjects had been suffering from a disorder of attention since childhood. He reported that he was able to concentrate better during treatment.

10 As a result of his increased concentration, he was able to complete a music project, which would normally have required more time, in one sitting. A second volunteer reported that he was less distracted and was able to concentrate on specific tasks longer during treatment with donezipil hydrochloride. These benefits wore off after treatment was discontinued.

15 Collectively, these results indicate that the administration of cholinesterase inhibitors, and in particular the compounds of the invention, surprisingly improves attention in humans, including persons with impaired memory such as Alzheimer's patients, healthy volunteers given a task to perform, and persons suffering from disorders of attention such as ADD.

What is Claimed is

1. A method for treating an attention disorder in a human in need of such treatment which comprises administering an effective amount of a cyclic amine  
 5 compound of the formula



10 wherein

r is an integer of 1 to 10, R<sup>22</sup> is hydrogen or methyl

and the R<sup>22</sup> radicals can be the same or different when r is from 2 to 10;

K is phenalkyl or phenalkyl having a substituent on the phenyl ring;

S is hydrogen or a substituent on the phenyl ring, and

15 t is an integer of 1 to 4, with the proviso that (S)t can be a methylenedioxy group or an ethylenedioxy group joined to two adjacent carbon atoms of the phenyl ring; and

q is an integer of 1 to 3

or a pharmacologically acceptable salt thereof.

20

2. The method of claim 1 wherein said cyclic amine compound is selected from the group consisting of:

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-ylidene)methylpiperidine,

25

1-benzyl-4-((5-methoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-diethoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-methylenedioxy-1-indanon)-2-yl)methylpiperidine,

1-(m-nitrobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

1-cyclohexymethyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

30

1-(m-florobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)propylpiperidine,

1-benzyl-4-((5-isopropoxy-6-methoxy-1-indanon)-2-yl)methylpiperidine  
and  
1-benzyl-4-((5,6-dimethoxy-1-oxoindanon)-2-yl)propenylpiperidine.

5           3.       The method of claim 1 wherein said cyclic amine compound is  
1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine.

4.       The method of claim 1, wherein the compound is administered in a  
daily dose of from about 1 to about 100 mg.

10          5.       The method of claim 2, wherein the compound is administered in a  
daily dose of from about 1 to about 100 mg.

15          6.       The method of claim 3, wherein the compound is administered in a  
daily dose of from about 1 to about 100 mg.

7.       The method of claim 1, wherein the compound is administered in  
a daily dose of from about 5 to about 10 mg.

20          8.       The method of claim 2, wherein the compound is administered in  
a daily dose of from about 5 to about 10 mg.


9.       The method of claim 3, wherein the compound is administered in  
a daily dose of from about 5 to about 10 mg.

25          10.      A method for treating an attention disorder in a human in need of  
such treatment which comprises administering an effective amount of a cholinesterase  
inhibitor.

11. A method for improving attention in a human in need of such treatment which comprises administering an effective amount of a cholinesterase inhibitor.

5

12. A method according to claim 10, wherein the cholinesterase inhibitor is a cyclic amine compound of the formula



10

wherein

r is an integer of 1 to 10, R<sup>22</sup> is hydrogen or methyl

and the R<sup>22</sup> radicals can be the same or different when r is from 2 to 10;

K is phenalkyl or phenalkyl having a substituent on the phenyl ring;

15

S is hydrogen or a substituent on the phenyl ring, and

t is an integer of 1 to 4, with the proviso that (S)t can be a methylenedioxy group or an ethylenedioxy group joined to two adjacent carbon atoms of the phenyl ring; and

q is an integer of 1 to 3

20 or a pharmacologically acceptable salt thereof.

13. The method of claim 12 wherein said cyclic amine compound is selected from the group consisting of:

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

25

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-ylidene)methylpiperidine,

1-benzyl-4-((5-methoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-diethoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-methylenedioxy-1-indanon)-2-yl)methylpiperidine,

1-(m-nitrobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

30

1-cyclohexymethyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

1-(m-florobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)propylpiperidine,  
1-benzyl-4-((5-isopropoxy-6-methoxy-1-indanon)-2-yl)methylpiperidine

and

1-benzyl-4-((5,6-dimethoxy-1-oxoindanon)-2-yl)propenylpiperidine.

5

14. The method of claim 12 wherein said cyclic amine compound is  
1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine.

15. The method of claim 12 wherein the compound is administered in  
10 a daily dose of from about 5 to about 10 mg.

16. The method of claim 13 wherein the compound is administered in  
a daily dose of from about 5 to about 10 mg.

15 17. The method of claim 14 wherein the compound is administered in  
a daily dose of from about 5 to about 10 mg.

# INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/IB 98/00508

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 A61K31/445

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	D.L. KIRKBY ET AL.: "Effects of anticholinesterasedrugs tacrine and e2020, the 5HT3 antagonist ondansetron and the H3 antagonist thioperamide, in models of cognition and cholinergic function." BEHAVIOURAL PHARMACOL., vol. 7, no. 6, 1996, pages 513-525, XP002068916 see the whole document -----	1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

22 June 1998

03/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T